Eosinophilic Gastroenteritis Market Poised for Phenomenal Expansion During the Forecast Period (2023-32) - Estimates DelveInsight | Key Companies - Allakos (Lirentelimab), AstraZeneca (Benralizumab)

Eosinophilic Gastroenteritis (EGE) market size in the seven major markets was USD 74.7 million in 2020, which is expected to grow by 2032. As per DelveInsight, the Eosinophilic Gastroenteritis Market is anticipated to evolve immensely in the coming years owing to the rise in the number of cases and the launch of novel therapies in the market.

DelveInsight's "Eosinophilic Gastroenteritis Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Eosinophilic Gastroenteritis Market Size and Share in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The market report covers emerging drugs, treatment practices, market share of individual Eosinophilic Gastroenteritis therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Eosinophilic Gastroenteritis treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of opportunities and assess the underlying potential of the market.

Eosinophilic Gastroenteritis: An Overview
Eosinophilic Gastroenteritis (EGE) is a rare digestive disease characterized by the triad of eosinophilic infiltratio of segments of the gastrointestinal tract, abnormalities of gastrointestinal function (varying from dyspepsia and obstruction to diarrhea and ascites), and exclusion of other diseases with peripheral eosinophilia.

There is no single diagnostic test or procedure that would point directly to the diagnosis of EGE, and there are no strict or uniform diagnostic criteria for it. Diagnostic evaluation of the patient with suspected EGE should include complete blood cell count and differential, erythrocyte sedimentation rate, C reactive protein, amylase, stool studies for ova and parasites, upper and lower gastrointestinal endoscopy with biopsies, bone marrow biopsy, allergen studies (skin testing and RASTs), and IgE and IL-5 levels. The underlying molecular mechanisms predisposing to this disease are unknown, but it seems that hypersensitivity response plays a major role in its pathogenesis, as many patients have a history of seasonal allergies, food sensitivities, asthma, and eczema.

The management options for Eosinophilic Gastroenteritis include both dietary and pharmacological approaches, with corticosteroids being the mainstay of therapy and highly effective. Although spontaneous remission is reported in around 30-40% of EGE cases, most patients require ongoing treatment. An alternative therapeutic armamentarium includes mast-cell stabilizers, leukotriene antagonists, antihistamines, immunomodulators, and biological agents.

Eosinophilic Gastroenteritis Market Key Facts
• In 2021, among the 7MM, the total prevalent cases of Eosinophilic Gastroenteritis were the highest in the US (more than 31,000 cases), and the lowest in Spain (around 2,800 cases).
• There were around 16,500 males and 15,000 females affected by Eosinophilic Gastroenteritis in the United States in 2021.
• Among EU5 countries, Germany had the highest number of prevalent cases of Eosinophilic Gastroenteritis (around 4,400 cases) in 2021.
• Spain had the lowest prevalent population of Eosinophilic Gastroenteritis (around 2,800 cases) in 2021.
• The unmet needs, including lack of curative therapies, need for therapies with minimal toxicity profile, high clinical and economic burden, and high cost of approved therapies, are driving opportunities in the market.

Discover How Eosinophilic Gastroenteritis Market Will Grow by 2032:
https://www.delveinsight.com/report-store/eosinophilic-gastroenteritis-ege-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Eosinophilic Gastroenteritis Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Eosinophilic Gastroenteritis therapies in the market. It also provides a detailed assessment of the Eosinophilic Gastroenteritis market drivers & barriers, unmet needs, and emerging technologies.

The report gives complete detail of the market trend for each marketed Eosinophilic Gastroenteritis drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MOA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

Eosinophilic Gastroenteritis Epidemiology
The epidemiology section covers detailed insights into the historical, and current Eosinophilic Gastroenteritis patient pool and forecasted epidemiology trends for every seven major countries (7MM) from 2019 to 2032.

The Report Covers the Eosinophilic Gastroenteritis Epidemiology Segmented as -
• Total Prevalent Cases of Eosinophilic Gastroenteritis [2019-2032]
• Gender-specific Cases of Eosinophilic Gastroenteritis [2019-2032]
• Age-specific Cases of Eosinophilic Gastroenteritis [2019-2032]

Get Key Insights Into the Evolving Eosinophilic Gastroenteritis Epidemiology Trends @
https://www.delveinsight.com/report-store/eosinophilic-gastroenteritis-ege-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Eosinophilic Gastroenteritis Drugs Uptake and Pipeline Development Activities
The drugs' uptake section focuses on the rate of uptake of the potential drugs recently launched in the Eosinophilic Gastroenteritis market or expected to be launched during the study period. The analysis covers the market share by Eosinophilic Gastroenteritis drugs, patient uptake by therapies, and sales of each drug.

The report's drugs uptake section helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs. It allows the comparison of the drugs based on market share and size, which again will be helpful in investigating factors important in understanding the market dynamics and in making financial and regulatory decisions.

The report also covers the Eosinophilic Gastroenteritis Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Explore More About Ongoing Pipeline Development Activities @
https://www.delveinsight.com/sample-request/eosinophilic-gastroenteritis-ege-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Eosinophilic Gastroenteritis Therapeutics Assessment
There are no FDA approved medications specifically for EGE. Fifty to seventy-five percent of patients with EGE have concomitant allergies or atopic disorders. Recognizing the food allergen and dietary restrictions is an integral part of EG management. Different management strategies have been used for patients with EGE. The major ones include both dietary and pharmacological approaches, with corticosteroids being the mainstay of therapy and highly effective.

The alternative therapeutic armamentarium includes PPI inhibitors, mast-cell stabilizers, leukotriene antagonists, antihistamines, immunomodulators, and biological agents. To counter unmet market needs and provide better treatment choices for EGE, several market players are working robustly either on single-agent novel molecules or on combination and dose modification of standard therapies. Several therapies are expected to be launched in the study period, likely to drive market growth during the study period.

Leading Companies in the Eosinophilic Gastroenteritis Therapeutics Market Include
• Allakos
• AstraZeneca
And Many Others

Emerging and Marketed Eosinophilic Gastroenteritis Therapies Covered in the Report Include
• Lirentelimab: Allakos
Lirentelimab/AK002 is an investigational, non-fucosylated IgG1 monoclonal antibody targeting Siglec-8. Lirentelimab blocks multiple inflammatory pathways by targeting Siglec-8, an inhibitory receptor. The binding to Siglec-8 induces inhibition of mast cells, apoptosis of tissue eosinophils, and depletion of blood eosinophils by antibody-dependent cellular cytotoxicity (ADCC).

• Benralizumab: AstraZeneca
Benralizumab (Fasenra) is a humanized fucosylated, monoclonal antibody (IgG1, kappa) that directly binds to the alpha subunit of the human interleukin-5 receptor (IL-5Rα) with a dissociation constant of 11 pM. The IL-5 receptor is expressed on the surface of eosinophils and basophils.

Learn More About the Emerging Therapies & Key Companies in the Eosinophilic Gastroenteritis Therapeutics Market:
https://www.delveinsight.com/sample-request/eosinophilic-gastroenteritis-ege-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Eosinophilic Gastroenteritis Competitive Intelligence Analysis
4. Eosinophilic Gastroenteritis Market Overview at a Glance
5. Eosinophilic Gastroenteritis Background and Overview
6. Eosinophilic Gastroenteritis Patient Journey
7. Eosinophilic Gastroenteritis Epidemiology and Patient Population
8. Eosinophilic Gastroenteritis Treatment Algorithm, Current Treatment, and Medical Practices
9. Eosinophilic Gastroenteritis Unmet Needs
10. Key Endpoints of Eosinophilic Gastroenteritis Treatment
11. Eosinophilic Gastroenteritis Marketed Products
12. Eosinophilic Gastroenteritis Emerging Therapies
13. Eosinophilic Gastroenteritis Seven Major Market Analysis
14. Attribute Analysis
15. Eosinophilic Gastroenteritis Market Outlook (7 major markets)
16. Eosinophilic Gastroenteritis Access and Reimbursement Overview
17. KOL Views on the Eosinophilic Gastroenteritis Market.
18. Eosinophilic Gastroenteritis Market Drivers
19. Eosinophilic Gastroenteritis Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The table of contents is not exhaustive; the final content may vary.

Download the Sample PDF to Get Detailed Insights About the Report's Offerings @
https://www.delveinsight.com/sample-request/eosinophilic-gastroenteritis-ege-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

-------------------------------------------- xx --------------------------------------------
Other Trending Healthcare Reports by DelveInsight
Anti-hypertension Market
https://www.delveinsight.com/report-store/anti-hypertension-market

Lower-Limb Spasticity Market
https://www.delveinsight.com/report-store/lower-limb-spasticity-market

Glioblastoma Market
https://www.delveinsight.com/report-store/glioblastoma-market

Cancer Cachexia (CC) Market
https://www.delveinsight.com/report-store/cancer-cachexia-cc-market-insights

Hepatitis C Market
https://www.delveinsight.com/report-store/hepatitis-c-market

Open-Angle Glaucoma Market
https://www.delveinsight.com/report-store/open-angle-glaucoma-market

Gastroesophageal Reflux Disease (GERD) Market
https://www.delveinsight.com/report-store/gastroesophageal-reflux-disease-gerd-market

Duchenne Muscular Dystrophy Market
https://www.delveinsight.com/report-store/duchenne-muscular-dystrophy-market

Helicobacter Pylori Infections Market
https://www.delveinsight.com/report-store/helicobacter-pylori-infections-market

Cerebral Infarction Market
https://www.delveinsight.com/report-store/cerebral-infarction-market

Gastroesophageal Reflux Disease (GERD) Market
https://www.delveinsight.com/report-store/gastroesophageal-reflux-disease-gerd-market

Papilloma Market
https://www.delveinsight.com/report-store/papilloma-market

Peripheral Neuritis Market
https://www.delveinsight.com/report-store/peripheral-neuritis-market

Renal Insufficiency Market
https://www.delveinsight.com/report-store/renal-insufficiency-market

Dysthymia Market
https://www.delveinsight.com/report-store/dysthymia-market

Persistent Depressive Disorder Market
https://www.delveinsight.com/report-store/persistent-depressive-disorder-market

Relapsing Multiple Sclerosis (RMS) Market
https://www.delveinsight.com/report-store/relapsing-multiple-sclerosis-rms-market

Asthma Market
https://www.delveinsight.com/report-store/asthma-market

Helicobacter Pylori Infections Market
https://www.delveinsight.com/report-store/helicobacter-pylori-infections-market

Corneal Dystrophy Market
https://www.delveinsight.com/report-store/corneal-dystrophy-market

Peripheral Vascular Devices Global Market
https://www.delveinsight.com/report-store/peripheral-vascular-devices-market

Physiotherapy Equipment Market Concussions Market
https://www.delveinsight.com/report-store/concussions-market

Herpes Simplex Market
https://www.delveinsight.com/report-store/herpes-simplex-market

Hairy Cell Leukemia (HCL) Market
https://www.delveinsight.com/report-store/hairy-cell-leukemia-hcl-market

Contact Info:
Shruti Thakur
Manager (Marketing & Branding)
Email: info@delveinsight.com

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.